To include your compound in the COVID-19 Resource Center, submit it here.

Celltech Group cancer, autoimmune, inflammation news

CCH will discontinue its in-house target discovery activities to focus on in-licensing targets. The company will close

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE